Jong Hyuk Kim, DVM, PhD

Assistant Professor, Department of Veterinary Clinical Sciences

Jong Hyuk Kim

Contact Info

[email protected]

Office Phone 612-624-3612 (Minnea

Lab Phone 612-626-6890

Office Address:
Veterinary Clinical Sciences
C325 VMC
1365 Gortner Ave
St Paul, MN 55108

Masonic Cancer Center
425 East River Parkway
Minneapolis, MN 55455

Mailing Address:
Veterinary Clinical Sciences
Room 339 VetMedCtrS
6192A (Campus Delivery Code)
1352 Boyd Ave
St Paul, MN 55108

Ph.D, Konkuk University

DVM, Konkuk University


Dr. Jong Hyuk Kim is an Assistant Professor of Oncology and Comparative Medicine at the University of Minnesota College of Veterinary Medicine. He earned his DVM from Konkuk University in South Korea. He received his Ph.D in Veterinary Pathology from the same school, where he established veterinary and comparative oncology research. Dr. Kim has a strong track record for publication in animal cancers and comparative oncology. His research interest is to define fundamental mechanisms of cancers, particularly aggressive metastatic sarcomas such as osteosarcoma and hemangiosarcoma. His team focuses on creation of novel in vitro models using sophisticated molecular approaches and development of a novel immunotherapy for sarcomas. 

Awards & Recognition

  • Award for Abstract Excellence from the 7th International Conference on Advances in Canine and Feline Genomics and Inherited Diseases, 2013
  • Travel Grant from Morris Animal Foundation, 2013
  • Fellowship Training Grant from Morris Animal Foundation, 2012
  • Academic Excellence Award in the Ph.D. Commencement, 2011
  • Oral Presentation Award from the Korean Society of Veterinary Science, 2010
  • Hi Seoul Scholarship from Seoul Ministry of Education, 2010

Professional Associations

Masonic Cancer Center - Genetic Mechanisms program

American Associations of Cancer Research 

Minnesota Veterinary Medical Association


Research Summary/Interests

Dr. Kim's research interest is to study the pathogenesis of cancers in the field of veterinary and comparative oncology. Our research mainly focuses on determining genetic and molecular mechanisms of bone and soft tissue sarcomas in animals and humans. Specifically, we have developed a novel, molecular and functional subclassification of canine hemangiosarcoma using next-generation sequencing technology and bioinformatics analysis. We establish comparative approaches to apply the findings for understanding human angiosarcoma.

We develop in vitro sarcoma models using induced pluripotent stem cells as well as establish chromatin accessibility and mutational landscape in osteosarcoma and hemangiosarcoma. Our goals are to identify oncogenic pathways associated with the chaotic genomic and epigenomic events in osteosarcoma and hemangiosarcoma and to develop effective therapeutic approaches for the aggressive, genetically complex sarcomas.

In addition, we seek to understand tumor immunity in sarcomas to develop a novel immuno-therapeutic strategy:

(a) We characterize the prognostic significance of the intrinsic host immune response in osteosarcoma to understand modulation of the tumor biology by inflammation and immunity.

(b) We identify microRNAs in osteosarcoma that impair T cell activation at the tumor site and in the draining lymph node, creating immunologically barren tumors. By this approach, we will understand the mechanisms of resistance to immunotherapy.

(c) Another project is to develop a novel immunotherapy for sarcomas using combination oncolytic VSV and IL-18 superkine. The goal is to define safety and efficacy of immunotherapy that combines an oncolytic virus to initiate an immune response with an IL-18 analog to expand and sustain the response.

Research Funding Grants

  • Discovery and Pathogenic Significance of Chromosome Translocations in Canine Hemangiosarcoma. National Canine Cancer Foundation, Principal Investigator
  • Slug and Interleukin-8 in Self-Renewal of Cancer Stem Cells in Canine Hemangiosarcoma. Morris Animal Foundation, Principal Investigator
  • Discovery and Pathogenetic Significance of Chromosome Translocations in Angiosarcoma. National Cancer Institute, co-Investigator
  • Mechanisms of Resistance to Immunotherapy in Osteosarcoma. United States Department of Defense, co-Investigator
  • Novel Immunotherapy for Sarcomas using Combination Oncolytic VSV and IL-18 Superkine, The V foundation, co-Investigator
  • Tumor on a Chip – 3D Printed Heterogeneous Tumor Platform for Cancer Cell Migration. UMN Physical Sciences in Oncology Center, co-Investigator
  • Understanding Topological Organization and Metastasis of Sarcoma using a Bioprinted In Vitro Tumor Model. UMN Physical Sciences in Oncology Center, co-Investigator
  • Chromatin Accessibility and the Convergent Oncogenic Pathways of Angiosarcomas. United States Department of Defense, Principal Investigator
  • Reprogramming the Tumor Immune Niche in Canine Hemangiosarcoma.AKC Canine Health Foundation, Principal Investigator
  • A Novel Approach Combining Oncolytic Virotherapy and Dual Immune Checkpoint Blockade for Metastatic Osteosarcoma. United States Department of Defense,Co-Investigator


  • Cheng N, Schulte AJ, Santosa F, Kim JH. Machine learning application identifies novel gene signatures from transcriptomic data of spontaneous canine hemangiosarcoma. Brief Bioinform. 2020 In Press
  • Kim JH, Megquier K, Sarver AL, Thomas R, Song JM, Kim YT, Cheng N, et al. Genomically complex human angiosarcoma and canine hemangiosarcoma establish convergent angiogenic transcriptional programs. bioRxiv preprint. doi:
  • Kim JH. PIK3CA mutations matter for cancer in dogs. Res Vet Sci. 2020 Sep 8;133:39-41. doi: 10.1016/j.rvsc.2020.09.001.
  • Megquier K, Turner-Maier J, Swofford R, Kim JH, et al. Comparative genomics reveals shared mutational landscape in canine hemangiosarcoma and human angiosarcoma. Mol Cancer Res. 2019 Dec;17(12):2410-2421.
  • Kim JH. Interleukin-8 and in the tumor immune niche: lessons from comparative oncology. In: Birbrair A. (eds) Tumor Microenvironment. Adv Exp Med Biol, vol 1240. Feb 15, 2020.
  • Langsten K, Kim JH, Sarver AL, Dewhirst M, Modiano JF. Comparative approach to the temporo-spatial organization of the tumor microenvironment. Front Oncol. 2019, 9, 1185.
  • Modiano JF and Kim JH. The Etiology of Cancer: The Genetic Basis of Cancer. In: Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition. Published Oct 15, 2019.
  • Kim JH, Frantz AM, Sarver AL, et al. Modulation of fatty acid metabolism and immune suppression are features of in vitro tumor sphere formation in ontogenetically distinct dog cancers. Vet Comp Oncol. 2018 Mar;16(1):E176-E184.
  • Im KS, Graef AJ, Breen M, Lindblad-Toh K, Modiano JF, Kim JH. Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma. Vet Comp Oncol. 2017 Jun;15(2):315-327.
  • Borgatti A, Koopmeiners JS, Sarver AL, Winter AL, Stuebner K, Todhunter D, Rizzardi A, Henriksen JC, Schmechel S, Forster CL, Kim JH, et al. Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR. Mol Cancer Ther. 2017 May;16(5):956-965.
  • Kim JH, Furrow E, Ritt MG, et al. Anti-insulin immune responses are detectable in dogs with spontaneous diabetes. PloS One. 2016 Mar 31;11(3):e0152397.
  • Kim JH, Graef AJ, Dickerson EB, et al. Pathobiology of hemangiosarcoma in dogs: research advances and future perspectives. Vet Sci. 2015, 2(4), 388-405.
  • Rodriguez AM, Graef AJ, LeVine DN, Cohen IR, Modiano JF, Kim JH. Association of sphingosine-1-phosphate (S1P)/S1P receptor-1 pathway with cell proliferation and survival in canine hemangiosarcoma. J Vet Intern Med. 2015 Jul;29(4):1088-97.
  • Tonomura N, Elvers I, Thomas R, Megquier K, Turner-Maier J, Howald C, Sarver AL, Swofford R, Frantz AM, Ito D, Mauceli E, Arendt M, Noh HJ, Koltookian M, Biagi T, Fryc S, Williams C, Avery AC, Kim JH, et al. Genome-wide association study identifies shared risk loci common to two malignancies in golden retrievers. PLoS Genet. 2015 Feb 2;11(2):e1004922
  • Kim JH, Frantz AM, Anderson KL, et al. Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment. Exp Cell Res, 2014 Apr 15;323(1):155-164.
  • Gorden BH, Kim JH*, Sarver AL, et al. Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. Am J Pathol. 2014 Apr;184(4):985-95. *Co-first author
  • Kim JH, Chon SK, Im KS, et al. Infiltrating Foxp3-positive regulatory T cells and histopathological features in canine classical and spermatocytic seminoma. Reprod Domest Anim. 2013 Apr;48(2):218-22.
  • Kim JH, Hur JH, Lee SM, et al. Correlation of Foxp3 positive regulatory T cells with prognostic factors in canine mammary carcinomas. Vet J. 2012 Jul;193(1):222-7.
  • Kim JH, Im KS, Kim NH, et al. Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study. Vet J. 2011 Sep;189(3):318-22.
  • Kim JH, Yu CH, Yhee JY, et al. Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours. J Comp Pathol. 2010 Feb-Apr;142(2-3):177-86.
  • Kim JH, Yu CH, Yhee JY, et al. Canine classical seminoma: a specific malignant type with human classifications is highly correlated with tumor angiogenesis. BMC Cancer. 2010 May 28;10:243.